Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
Immatics
What Does Immatics Do?
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biopharmaceutical company dedicated to the development of T cell receptor (TCR) based immunotherapies for the treatment of cancer patients. The Company is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Immatics’ pipeline includes T cell engaging receptor (TCER®) bispecifics and Adoptive Cell Therapies (ACTengine®) that are based on its proprietary target and TCR discovery platforms. Their approach focuses on identifying novel, cancer-specific targets and engineering high-affinity TCRs to redirect a patient's own T cells or soluble T cell engaging bispecifics to recognize and eradicate tumors.
Where Is Immatics's Headquarters?
HQ Function
The Tübingen headquarters serves as the central hub for Immatics' global operations, spearheading core research and development (R&D) activities, corporate strategy, and administrative functions. It is the birthplace of Immatics' proprietary XPRESIDENT® target discovery and TCR discovery platforms.
Notable Features:
The facility is situated within a prominent German biotechnology cluster, fostering collaborations and access to specialized talent. It houses state-of-the-art laboratories and office spaces designed to support cutting-edge research in immunotherapy.
Work Culture:
Immatics fosters a highly scientific, innovative, and collaborative work environment. The culture emphasizes teamwork among multidisciplinary groups focused on pioneering cancer immunotherapy research, driven by scientific rigor, a patient-centric mission, and a commitment to continuous learning and development.
HQ Significance:
The Tübingen headquarters is foundational to Immatics' pioneering work in TCR-based therapies. It is where the company's core scientific discoveries are made, driving the early-stage development of its innovative pipeline and underpinning its technological leadership in the field.
Values Reflected in HQ: The headquarters reflects Immatics' core values of innovation, scientific excellence, and dedication to patients through its advanced research infrastructure, collaborative workspaces, and location within a leading scientific community.
Location:
Immatics maintains a significant global presence focused on advancing its cancer immunotherapy pipeline. Its operations are anchored by its global headquarters in Tübingen, Germany, for research and corporate functions; its U.S. headquarters and cell therapy manufacturing site in Houston, Texas, for clinical development and U.S. operations; and its TCER® bispecifics manufacturing facility in Martinsried, Germany. This strategic distribution of sites enables Immatics to conduct research, discovery, clinical development, and manufacturing across key regions, primarily Europe and North America, to bring innovative treatments to cancer patients worldwide.
Street Address:
Paul-Ehrlich-Straße 15
City:
Tübingen
State/Province:
Baden-Württemberg
Country:
Germany
Where Else Does Immatics Operate Around the World?
Houston, Texas, USA
Address: 2130 W. Holcombe Blvd., Suite 850, Houston, TX 77030, USA
To spearhead clinical development and manufacturing operations in the United States, a key global market for oncology therapeutics, and to foster collaborations with leading U.S. cancer research institutions and medical centers.
Planegg-Martinsried (Munich), Germany
Address: Fraunhoferstraße 22, 82152 Planegg-Martinsried, Germany
To ensure high-quality, scalable manufacturing of proprietary bispecific immunotherapies within Europe, leveraging Germany's robust biotechnology infrastructure and expertise in biologics production.
Buying Intent Signals for Immatics
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Who's Leading Immatics? Meet the Executive Team
As of April 2025, Immatics' leadership includes:
Who's Investing in Immatics?
Immatics has been backed by several prominent investors over the years, including:
What Leadership Changes Has Immatics Seen Recently?
Over the past year (approx. May 2023 - May 2024), Immatics saw a key leadership appointment with Arnd Christ joining as Chief Business Officer. This followed the transition of Dr. Carsten Reinhardt from Chief Development Officer to a Strategic Advisor role. Additionally, a previously announced CFO transition was reversed, with Thomas Ulmer continuing in his position as Chief Financial Officer.
Departures
New Appointments:
What Technology (Tech Stack) Is Used byImmatics?
Discover the tools Immatics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Immatics Email Formats and Examples
Immatics typically utilizes a standard corporate email format. The most commonly observed pattern is 'firstname.lastname@immatics.com'. While variations might exist for specific individuals or roles, this format is generally reliable for reaching Immatics employees.
firstname.lastname@immatics.com
Format
john.doe@immatics.com
Example
85%
Success rate
What's the Latest News About Immatics?
Immatics N.V. / GlobeNewswire • May 9, 2024
Immatics Reports First Quarter 2024 Financial Results and Provides Business Update
Immatics announced its financial results for Q1 2024, highlighting progress in its clinical pipeline, including updates on its ACTengine® IMA203 (PRAME) and TCER® IMA401 (MAGEA4/8) programs. The company reported a strong cash position of €393.0 million ($422.9 million), expected to fund operations into 2027....more
Immatics N.V. / GlobeNewswire • April 2, 2024
Immatics Announces Presentation of Initial Phase 1b Dose Escalation Data for IMA203CD8 in Patients with PRAME-positive Solid Tumors at AACR Annual Meeting 2024
Immatics presented initial data from its Phase 1b dose escalation cohort for IMA203CD8, a PRAME-targeted T cell therapy, at the AACR Annual Meeting. The data showed encouraging early anti-tumor activity and a manageable safety profile in heavily pre-treated cancer patients....more
Immatics N.V. / GlobeNewswire • March 26, 2024
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Include Multiple Cell Therapy Programs
Immatics and Bristol Myers Squibb announced an expansion of their existing collaboration. BMS gained an option to license, develop, and commercialize multiple allogeneic TCR-T/CAR-T programs developed by Immatics. Immatics received an upfront payment of $60 million and is eligible for milestone payments and royalties....more
Immatics N.V. / GlobeNewswire • January 9, 2024
Immatics Appoints Arnd Christ as Chief Business Officer
Immatics announced the appointment of Arnd Christ as its new Chief Business Officer, effective January 8, 2024. He succeeded Dr. Carsten Reinhardt, who transitioned to a role as Strategic Advisor....more
Highperformr's free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Immatics, are just a search away.